Clinical assessment of ChAdOx1 vectored vaccines against emerging pathogens by Moreira Folegatti, P

CMV-associated T cell and NK cell terminal differentiation does not impact immunogenicity of ChAdOx1 vaccination by Sharpe, HR, Provine, NM, Bowyer, GS, Moreira Folegatti, P, Belij-Rammerstorfer, S, Flaxman, A, Makinson, R, Hill, AV, Ewer, KJ, Pollard, AJ, Klenerman, P, Gilbert, S, Lambe, T

Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm sub-study of a phase 2/3 clinical trial by Frater, J, Ewer, K, Ogbe, A, Pace, M, Adele, S, Adland, E, Aley, P, Ali, M, Ansari, M, Bittaye, M, Brown, A, Brown, H, Cappuccini, F, Dejnirattisai, W, Dold, C, Moreira Folegatti, P, Fowler, J, Jenkin, D, Makinson, R, Marchevsky, N, Mujadidi, Y, Parolini, L, Plested, E, Ramasamy, M, Rhead, S, Robinson, H, Robinson, N, Rongkard, P, Tipoe, T, Zacharopoulou, P, Barnes, E, Goulder, P, Klenerman, P, Screaton, G, Hill, A, Gilbert, S, Pollard, AJ, Lambe, T